Professor Ljubić presented a groundbreaking new technology in regenerative medicine at the International Congress of Reproductive Medicine 2024 in Doha, Qatar. The innovation involves the use of two types of cells—mesenchymal and hematopoietic stem cells—in the treatment of ovarian function decline. This procedure represents an advancement of the SEGOVA program and has been named Dual Stem Cell Activation of the Ovary. The professor’s lecture focuses on this novel technology, covering its mechanisms of action, beneficial effects, and the potential risks associated with such procedures.
